KZIA
HealthcareKazia Therapeutics Limited
$5.72
+$0.72 (+14.40%)
Jan 5, 2026
Price History (1Y)
Analysis
Kazia Therapeutics Limited is a biotechnology company operating in the healthcare sector. With a market capitalization of $64.84M, it has a relatively small scale compared to larger industry players. The company's revenue for the trailing twelve months (TTM) stands at $1.83M, and it employs 6 individuals. Financially, Kazia Therapeutics Limited is currently operating at a loss, with a net income of -$20,702,000 for the TTM. Its profitability metrics paint a concerning picture: the company has an operating margin of -268.4% and a profit margin of 0.0%. The return on assets (ROA) stands at -64.3%, indicating significant losses relative to its assets. On the other hand, the company's cash balance is $4.34M, while it has a relatively small debt burden of $396,000. The valuation metrics for Kazia Therapeutics Limited are not favorable. The forward P/E ratio is -771.05, and the price-to-book ratio is -1.67. Additionally, the company's revenue growth rate over the past year stands at -27.2%. Dividend payments do not appear to be a consideration for investors, given the payout ratio of 0.0% and the absence of dividend yield information.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Visit website →Key Statistics
- Market Cap
- $64.84M
- P/E Ratio
- N/A
- 52-Week High
- $17.40
- 52-Week Low
- $2.86
- Avg Volume
- 733.25K
- Beta
- 1.75
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Australia
- Employees
- 6